New screening method may detect twice as many cases of ovarian cancer
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers from University College London have developed a new screening tool that can detect twice as many women with ovarian cancer as standard approaches.
Specifically, the study showed that the new method, which detects changes in CA125 levels, could detect cancer in 86% of women with invasive epithelial ovarian cancer.
CA125 is a protein biomarker in the blood of women that has been linked to ovarian cancer. A statistical test then predicts the woman's risk of having ovarian cancer.
"CA125 as a biological marker for ovarian cancer has been called into question. Our findings indicate that this can be an accurate and sensitive screening tool, when used in the context of a woman's pattern of CA125 over time," said Professor Ian Jacobs, chief investigator of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), an co-inventor of the statistical approach.
"What's normal for one woman may not be so for another. It is the change in levels of this protein that's important. My hope is that when the results of UKCTOCS are available this approach will prove capable of detecting ovarian cancer early enough to save lives."
The study evaluated 46,237 women who were screened annually for ovarian cancer over a 14-year period.
A new screening tool can detect twice as many women with ovarian cancer as standard approaches.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|